January 18, 2017 10:20 AM ET

Capital Markets

Company Overview of Laidlaw & Company (UK) Ltd.

Company Overview

Laidlaw & Company (UK) Ltd. provides investment banking and wealth management services to institutions and individuals in the United States and the United Kingdom. Its investment banking services include capital raising through placement of equity with institutional and high net worth retail investors; placement of debt and mezzanine capital with institutional investors; acquisition financing; arrangement of national exchange listings; the United States trading markets; AIM-listed transactions in the United Kingdom market; and initial public offerings. The company’s investment banking services also comprise advisory services on acquisitions, divestitures, fairness opinions, financial restruc...

546 5th Avenue

5th Floor

New York, NY 10036

United States





Key Executives for Laidlaw & Company (UK) Ltd.

Chief Executive Officer
Managing Partner and Head of Capital Markets
Executive Director of Investment Banking and Head of Laidlaw Private Equity
Age: 66
Senior Managing Director
Senior Managing Director, Private Placements
Compensation as of Fiscal Year 2016.

Laidlaw & Company (UK) Ltd. Key Developments

Relmada Therapeutics, Inc. Files Amended Complaint Against Laidlaw & Company (UK) Ltd

Relmada Therapeutics Inc. announced that it has filed a motion to amend its complaint against Laidlaw &Company (UK) Ltd. (Laidlaw) in the U.S. District Court for the District of Nevada. The motion to file an amended complaint is part of the lawsuit that the company had previously filed in the Nevada District Court. The amended complaint includes an additional legal claim based on Laidlaw's breach of the fiduciary duty that it owed to Relmada when Laidlaw disclosed confidential information that it acquired in its capacity as the company's investment banker. Relmada is also seeking monetary damages arising from fees and costs that it incurred responding to Laidlaw's false and misleading proxy materials in December 2015. Relmada noted that the Nevada court previously issued a temporary restraining order and associated injunction against Laidlaw and its principals, Matthew Eitner and James Ahern, as a result of their dissemination of false and misleading proxy materials. Relmada's Board believes Laidlaw must compensate the Company for the damages it has suffered as a result of Laidlaw's actions, and that Laidlaw must be prevented from harming the company in the future.

Laidlaw & Company, LTD. Announces Executive Changes

Laidlaw & Company, LTD. announced the expansion of the London office with the addition of two team member: Richard Michalski, Senior Managing Director in Wealth Management and Bryan Kobel, Managing Director in Equity Capital Markets. The team will look to build on the current infrastructure and client base in the Wealth Management division and provide European healthcare companies and investors access to the US capital markets. Mr. Richard Michalski joined Laidlaw & Co. (Ltd) as Senior Managing Director in November 2010 from Aegis Capital, where he was a Senior Vice President. Mr. Bryan Kobel joined Laidlaw & Co. (Ltd) in March of 2012 from a small cap consulting company. Most recently, he was instrumental in helping to develop the US capital markets presence of Laidlaw & Co. since joining.

Relmada Therapeutics, Inc. Files Lawsuit against Laidlaw & Company and its Principals to Protect Interests of Relmada Stockholders

Relmada Therapeutics Inc. announced that it has filed a lawsuit against Laidlaw & Company (UK) Ltd. and its two principals, Matthew Eitner and James Ahern, in the U.S. District Court for the District of Nevada. Laidlaw previously served as an investment banker to Relmada. Using shares and confidential information gained from these services to Relmada, Laidlaw recently launched a contest to take effective control of the Company. Laidlaw and its principals have a history of violating U.S. financial regulations, which has resulted in numerous customer complaints, regulatory sanctions and monetary penalties. In its lawsuit, Relmada claims that Laidlaw and its principals are once again violating U.S. laws and regulations, including disseminating materially false and misleading information in its attempt to take effective control of Relmada. The lawsuit filed by Relmada claims that Laidlaw failed to comply with Securities and Exchange Commission (SEC) regulations, Relmada's Articles of Incorporation and Bylaws, and Nevada law, and seeks to enjoin Laidlaw from continuing to disseminate false and misleading information and from soliciting proxies from Relmada stockholders under false and misleading pretenses, and to correct the misinformation it has already issued.

Similar Private Companies By Industry

Company Name Region
@Visory LLC United States
1 Road Partners LLC United States
11T Partners, LLC United States
123Jump.com, Inc. United States
1509225 Ontario, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Laidlaw & Company (UK) Ltd., please visit www.laidlawltd.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.